Menu Search
Equities

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

6990:HKG.HS

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Actions
  • Price (HKD)165.60
  • Today's Change-1.50 / -0.90%
  • Shares traded290.57k
  • 1 Year change+91.45%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

  • Revenue in HKD (TTM)2.02bn
  • Net income in HKD-250.35m
  • Incorporated2016
  • Employees1.54k
  • Location
    Sichuan Kelun-Biotech Biopharmaceutical Co LtdNo. 666 Xinhua Avenue, Chengdu Cross-StrCHENGDU ChinaCHN
  • Websitehttp://www.kelun-biotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.